Annual accounts receivable:
$700.00K-$1.93M(-73.36%)Summary
- As of today (July 4, 2025), CLDX annual accounts receivable is $700.00 thousand, with the most recent change of -$1.93 million (-73.36%) on December 31, 2024.
- During the last 3 years, CLDX annual accounts receivable has risen by +$528.00 thousand (+306.98%).
- CLDX annual accounts receivable is now -77.86% below its all-time high of $3.16 million, reached on December 31, 2018.
Performance
CLDX Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$1.06M+$364.00K(+52.00%)Summary
- As of today (July 4, 2025), CLDX quarterly accounts receivable is $1.06 million, with the most recent change of +$364.00 thousand (+52.00%) on March 31, 2025.
- Over the past year, CLDX quarterly accounts receivable has dropped by -$1.61 million (-60.16%).
- CLDX quarterly accounts receivable is now -90.73% below its all-time high of $11.48 million, reached on September 30, 2008.
Performance
CLDX Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
CLDX Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -73.4% | -60.2% |
| 3 y3 years | +307.0% | +337.9% |
| 5 y5 years | -31.0% | -4.0% |
CLDX Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -73.4% | +307.0% | -60.2% | +996.9% |
| 5 y | 5-year | -73.4% | +307.0% | -60.2% | +996.9% |
| alltime | all time | -77.9% | +1490.9% | -90.7% | +8766.7% |
CLDX Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $1.06M(+52.0%) |
| Dec 2024 | $700.00K(-73.4%) | $700.00K(-17.8%) |
| Sep 2024 | - | $852.00K(-44.5%) |
| Jun 2024 | - | $1.53M(-42.6%) |
| Mar 2024 | - | $2.67M(+1.6%) |
| Dec 2023 | $2.63M(+657.3%) | $2.63M(+942.9%) |
| Sep 2023 | - | $252.00K(+113.6%) |
| Jun 2023 | - | $118.00K(-91.0%) |
| Mar 2023 | - | $1.31M(+278.7%) |
| Dec 2022 | $347.00K(+101.7%) | $347.00K(+83.6%) |
| Sep 2022 | - | $189.00K(+94.8%) |
| Jun 2022 | - | $97.00K(-60.1%) |
| Mar 2022 | - | $243.00K(+41.3%) |
| Dec 2021 | $172.00K(-90.5%) | $172.00K(-12.7%) |
| Sep 2021 | - | $197.00K(-60.3%) |
| Jun 2021 | - | $496.00K(-72.9%) |
| Mar 2021 | - | $1.83M(+1.4%) |
| Dec 2020 | $1.80M(+77.5%) | $1.80M(+115.0%) |
| Sep 2020 | - | $838.00K(+154.7%) |
| Jun 2020 | - | $329.00K(-70.3%) |
| Mar 2020 | - | $1.11M(+9.2%) |
| Dec 2019 | $1.01M(-67.9%) | $1.01M(+39.6%) |
| Sep 2019 | - | $727.00K(-37.9%) |
| Jun 2019 | - | $1.17M(-49.3%) |
| Mar 2019 | - | $2.31M(-27.0%) |
| Dec 2018 | $3.16M(+68.2%) | $3.16M(-0.4%) |
| Sep 2018 | - | $3.17M(-7.2%) |
| Jun 2018 | - | $3.42M(-14.9%) |
| Mar 2018 | - | $4.02M(+113.8%) |
| Dec 2017 | $1.88M(+5.4%) | $1.88M(-37.6%) |
| Sep 2017 | - | $3.01M(+121.7%) |
| Jun 2017 | - | $1.36M(-1.8%) |
| Mar 2017 | - | $1.38M(-22.4%) |
| Dec 2016 | $1.78M(+83.9%) | $1.78M(+13.0%) |
| Sep 2016 | - | $1.58M(+41.5%) |
| Jun 2016 | - | $1.12M(+31.8%) |
| Mar 2016 | - | $847.00K(-12.7%) |
| Dec 2015 | $970.00K(+127.2%) | $970.00K(+84.1%) |
| Sep 2015 | - | $527.00K(+21.4%) |
| Jun 2015 | - | $434.00K(-36.1%) |
| Mar 2015 | - | $679.00K(+59.0%) |
| Dec 2014 | $427.00K(-12.7%) | $427.00K(-85.3%) |
| Sep 2014 | - | $2.90M(+453.3%) |
| Jun 2014 | - | $525.00K(+72.1%) |
| Mar 2014 | - | $305.00K(-37.6%) |
| Dec 2013 | $489.00K | $489.00K(-45.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $890.00K(+7316.7%) |
| Jun 2013 | - | $12.00K(-88.5%) |
| Mar 2013 | - | $104.00K(+136.4%) |
| Dec 2012 | $44.00K(-74.1%) | $44.00K(-27.9%) |
| Jun 2012 | - | $61.00K(-64.1%) |
| Dec 2011 | $170.00K(-90.7%) | $170.00K(-16.7%) |
| Sep 2011 | - | $204.00K(-16.0%) |
| Mar 2011 | - | $243.00K(-46.7%) |
| Sep 2010 | - | $456.00K(-38.2%) |
| Jun 2010 | - | $738.00K(-14.1%) |
| Mar 2010 | - | $859.00K(-21.3%) |
| Sep 2009 | - | $1.09M(+7.7%) |
| Jun 2009 | - | $1.01M(-6.0%) |
| Mar 2009 | - | $1.08M(-41.0%) |
| Dec 2008 | $1.83M(+894.0%) | $1.83M(-84.1%) |
| Sep 2008 | - | $11.48M(+646.5%) |
| Jun 2008 | - | $1.54M(+3843.6%) |
| Mar 2008 | - | $39.00K(-28.4%) |
| Sep 2007 | - | $54.50K(-46.8%) |
| Jun 2007 | - | $102.40K(-57.1%) |
| Mar 2007 | - | $238.60K(+29.8%) |
| Dec 2006 | $183.80K(-56.1%) | $183.80K(-66.8%) |
| Sep 2006 | - | $554.40K(-24.6%) |
| Jun 2006 | - | $735.70K(+2.7%) |
| Mar 2006 | - | $716.20K(+71.2%) |
| Dec 2005 | $418.40K(-81.2%) | $418.40K(-92.6%) |
| Sep 2005 | - | $5.64M(+3.0%) |
| Jun 2005 | - | $5.48M(+497.6%) |
| Mar 2005 | - | $916.50K(-58.9%) |
| Dec 2004 | $2.23M(+51.4%) | $2.23M(+262.2%) |
| Sep 2004 | - | $615.80K(+14.0%) |
| Jun 2004 | - | $540.10K(-67.3%) |
| Mar 2004 | - | $1.65M(+12.2%) |
| Dec 2003 | $1.47M(+537.9%) | $1.47M(+159.1%) |
| Sep 2003 | - | $568.50K(-3.0%) |
| Jun 2003 | - | $585.80K(-7.7%) |
| Mar 2003 | - | $634.50K(+174.8%) |
| Dec 2002 | $230.90K(-13.6%) | $230.90K(-89.1%) |
| Sep 2002 | - | $2.12M(+847.9%) |
| Jun 2002 | - | $224.10K(-1.5%) |
| Mar 2002 | - | $227.50K(-14.9%) |
| Dec 2001 | $267.20K(-38.1%) | $267.20K(+65.4%) |
| Sep 2001 | - | $161.50K(-57.9%) |
| Jun 2001 | - | $383.50K(+119.1%) |
| Mar 2001 | - | $175.00K(-59.5%) |
| Dec 1999 | $431.70K | $431.70K |
FAQ
- What is Celldex Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Celldex Therapeutics?
- What is Celldex Therapeutics annual accounts receivable year-on-year change?
- What is Celldex Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly accounts receivable year-on-year change?
What is Celldex Therapeutics annual accounts receivable?
The current annual accounts receivable of CLDX is $700.00K
What is the all time high annual accounts receivable for Celldex Therapeutics?
Celldex Therapeutics all-time high annual accounts receivable is $3.16M
What is Celldex Therapeutics annual accounts receivable year-on-year change?
Over the past year, CLDX annual accounts receivable has changed by -$1.93M (-73.36%)
What is Celldex Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of CLDX is $1.06M
What is the all time high quarterly accounts receivable for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly accounts receivable is $11.48M
What is Celldex Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, CLDX quarterly accounts receivable has changed by -$1.61M (-60.16%)